2-oxindole has been researched along with 2019 Novel Coronavirus Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Babkov, DA; Bazanov, DR; Bezsonova, EN; Bunev, AS; Dubar, M; Grigor'eva, OB; Klochkov, VG; Lozinskaya, NA; Melekhina, DD; Sokolova, EV; Sosonyuk, SE; Spasov, AA | 1 |
| Babkov, D; Bezsonova, E; Klochkov, V; Lozinskaya, N; Othman, E; Sirotenko, V; Sosonyuk, S; Spasov, A | 1 |
2 other study(ies) available for 2-oxindole and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
3-Arylidene-2-oxindoles as Potent NRH:Quinone Oxidoreductase 2 Inhibitors.
Topics: COVID-19; Humans; Oxindoles; Quinone Reductases; Quinones | 2023 |
3-Arylidene-2-oxindoles as GSK3β inhibitors and anti-thrombotic agents.
Topics: COVID-19; Fibrinolytic Agents; Glycogen Synthase Kinase 3 beta; Humans; Oxindoles; Platelet Aggregation; Platelet Aggregation Inhibitors; Thrombosis | 2023 |